TABLE 1. Annual Awards and Expenditures of Section 317 Direct Assistance (DA) Vaccine Purchase Funds (in millions)

Year

New Funds

Rewarded Fundsa

Total Award

Expenditures

Percentage of Total Award Expendedb

1990

$149.0

$0.0

$149.0

$106.3

71%

1991

$112.9

$37.5

$150.3

$102.5

68%

1992

$156.2

$26.8

$183.1

$121.6

66%

1993

$171.2

$43.9

$215.1

$156.0

73%

1994

$136.2

$86.3

$222.5

$172.4

78%

1995c

$85.3

$77.0

$162.3

$96.3

59%

1996

$133.3

$11.0

$144.2

$111.2

77%

1997

$124.0

$34.7

$158.7

$128.4

81%

1998d

$108.2

$34.9

$143.1

$135.6

95%

1999e

$128.0

$6.0

$134.0

aFunds awarded in previous years but not obligated.

bBased on year-end unobligated balances for 1990-1997 reported to CDC as of 4/1/99.

c$53 million rescinded from unobligated balances in FY96 (comprised of funds from 1993, 1994, and 1995).

dCDC estimates for expenditures and percentage of 1998 award expen ded.

eProjected amounts for 1999. NOTES: (a) CDC notes that 1990 was the first year that grants were administered centrally, instead of by regional offices. There is limited background information on which to substantiate these amounts and as a result their accuracy is questionable. (b) In 1994, an additional $30,672,686 in appropriated vaccine purchase funds was paid directly to the Treasury for floor stocks excise taxes on behalf of all the grantees when the Vaccine Compensation Act was reauthorized.

SOURCE: Data provided by CDC.



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement